title: [Hepatitis delta: Clinical aspects and therapeutic perspectives].
abstract: HDV prevalence must not be disregarded, as the virus is associated with a higher severity of hepatic disease. All HBV carriers should be tested for HDV as well, at least once during the disease history, and in case of worsening of a chronic HBV hepatitis. Diagnosis should rely on anti-HDV antibody testing, and confirmed by HDV RNA detection and quantification by RT-qPCR. The only treatment available is pegylated alpha interferon. Optimal duration of treatment has not yet been proven, and relapses are common. Disease follow-up should be carried on even when SVR is obtained, in order to track late viral relapses, and fibrosis complications (such as HCC screening).
authors.affiliation: Centre de recherche en cancérologie de Lyon, UMR Inserm U1052, CNRS UMR 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard-Lyon 1 (UCBL), 69622 Villeurbanne cedex, France.
authors.forename: Dulce
authors.initials: D
authors.lastname: Alfaiate
authors.affiliation: Centre de recherche en cancérologie de Lyon, UMR Inserm U1052, CNRS UMR 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard-Lyon 1 (UCBL), 69622 Villeurbanne cedex, France; Hospices civils de Lyon (HCL), 69004 Lyon, France.
authors.forename: Clothilde
authors.initials: C
authors.lastname: Miaglia
authors.affiliation: Centre de recherche en cancérologie de Lyon, UMR Inserm U1052, CNRS UMR 5286, 69424 Lyon cedex 03, France; Université Claude-Bernard-Lyon 1 (UCBL), 69622 Villeurbanne cedex, France; Hospices civils de Lyon (HCL), 69004 Lyon, France. Electronic address: fabien.zoulim@inserm.fr.
authors.forename: Fabien
authors.initials: F
authors.lastname: Zoulim
mesh_terms: D003699:Hepatitis D / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans